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The risk for developing the alcohol dependence syndrome
(ADS) has a substantial genetic component. The human
thiamine transporter protein 2 (hTHTR2) is encoded by
the SLC19A3 gene, which is on chromosome 2q37.
hTHTR2 is responsible for the cellular uptake of thiamine
(B1), a water-soluble essential vitamin that plays a
fundamental and ubiquitous role in carbohydrate metabo-
lism. This gene was also found to be associated with biotin-
responsive basal ganglia disease, an autosomal recessive
metabolic disorder characterized by encephalopathy and
ophthalmoplegia (Ozand et al., 1998; Zeng et al., 2005).
Homozygous or compound heterozygous mutations in
SLC19A3 cause two distinct clinical phenotypes: biotin-
responsive basal ganglia disease and Wernicke’s-like
encephalopathy. Biotin and/or thiamine are effective
therapies for both diseases (Yamada et al., 2010). A missense
mutation in exon 5 of the SLC19A3 was found in 18 cases of
biotin/thiamine-responsive basal ganglion disease present-
ing with subacute encephalopathy and extrapyramidal signs
(Alfadhel et al., 2013). Kono et al. (2009) described two
Japanese brothers, who were both compound heterozygotes
for the K44E and E320Q mutations in SLC19A3, who
developed a syndrome of thiamine-responsive diplopia,
ophthalmoplegia and ataxia, similar to Wernicke’s ence-
phalopathy, despite normal serum thiamine levels (Kono
et al., 2009). Yamada et al. (2010) reported a pathogenic
homozygous mutation (c.958G>C, [p.E320Q]) in
SLC19A3 in four patients from a single family. They report
a wide variety of neurological signs in SLC19A3 mutation
carriers. Our previous unpublished research found that four
markers in the SLC19A3 gene showed significant allelic
association with Wernicke–Korsakoff syndrome (WKS) in a
sample of 120 cases when compared with normal controls.
In the present study, the entire SLC19A3 gene was
screened for DNA variation in a WKS subset (n=120) of
a UK ADS case–control sample comprised of 1032 alcohol-
dependent cases and 1022 controls. High resolution
melting curve analysis, which is based on the melting
characteristic of double-stranded DNA, was carried out
using a LightCycler 480 Real-Time PCR System (Roche,
Burgess Hill, UK). Genetic variation was validated with
Sanger DNA sequencing. Thirteen single nucleotide
variants were identified through high resolution melting
analysis. Two exon 3 variants that were predicted to cause
amino acid substitutions, 2:228563818T/C and
rs148144444, were selected for genotyping in the entire
ADS case–control sample using an allele-specific fluores-
cent PCR method (KasPar; LGC Genomics, Hoddesdon,
UK). Statistical analysis was carried out on the previously
unreported 2:228563818T/C change of a T to C substitu-
tion at position 228563 818 on chromosome 2. This variant
causes an R250G amino acid substitution in the largest
cytoplasmic domain of the protein and it is, therefore,
likely to affect post-translational function. rs148144444
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causes the amino acid change G141S which is likely to
exert an effect on protein phosphorylation and conforma-
tion because of the introduction of the aliphatic chain of
serine. Neither the cases nor the controls in the present
study had the SLC19A3 disease susceptibility variants that
have been reported previously (Zeng et al., 2005; Kono et al.,
2009). The minor allele of 2:228563818T/C was detected
in five ADS cases, but was absent in the control samples
(P=0.033). The minor allele of rs148144444 was detected
in five ADS cases and in four controls and was not
associated with ADS. Neither of these variants was present
in the 120 WKS cases in our ADS sample. Our data suggest
that genetic variation in the SLC19A3 thiamine transporter
at 2:228563818T/C may make a modest contribution
towards the genetic susceptibility to ADS.
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